GoAI
Get started
Nuvation Bio Inc. logo

Nuvation Bio Inc.

NUVB

NYSEHealthcareBiotechnology

Open in GoAI

Previous close

$6.93

+$0.10 · +1.46%

Aug 21, 4:00 PM ET

Pre-market

$6.97

+$0.04 · +0.58%

Aug 24, 7:31 AM ET

NUVB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

75

Undervalued

Momentum

64

Gaining

Sentiment

71

Bullish

Risk resilience

35

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David T. Hung
Listed since
Aug 26, 2020
Employees
305

Market position

Day range

Current $6.93

52-week range

Current $6.93

Open
$7.04
Previous close
$6.83
Volume
4.83M
0.8× average
Average volume
6.07M
Average daily volume
Market cap
2.41B USD
Beta
1.53
Market reference 1
50-day average
$6.08
+13.98% above average
200-day average
$5.8558
+18.35% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-15.95×
P/B (TTM)
9.52×
P/S (TTM)
14.16×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
93.94%
Operating margin
-81.00%
Net margin
-88.19%

Financial health

Debt / equity
0.99×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends848%-2198%-5243%-8289%Gross margin, FY2024: 10.10%Gross margin, FY2025: 86.58%Operating margin, FY2024: -7527.33%Operating margin, FY2025: -338.72%Net margin, FY2024: -7213.76%Net margin, FY2025: -325.31%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 10.10%. Gross margin FY2025 86.58%. Operating margin FY2024 -7527.33%. Operating margin FY2025 -338.72%. Net margin FY2024 -7213.76%. Net margin FY2025 -325.31%.

Income trends

Revenue

62.9M USD+698.96%

Operating income

−213.06M USD+64.05%

Net income

−204.63M USD+63.97%
Income trends across reported periods128.45M USD−133.76M USD−395.97M USD−658.18M USDRevenue, FY2024: 7.87M USDRevenue, FY2025: 62.9M USDOperating income, FY2021: −93.32M USDOperating income, FY2022: −119.73M USDOperating income, FY2023: −99.82M USDOperating income, FY2024: −592.63M USDOperating income, FY2025: −213.06M USDNet income, FY2021: −86.85M USDNet income, FY2022: −104.2M USDNet income, FY2023: −75.8M USDNet income, FY2024: −567.94M USDNet income, FY2025: −204.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 7.87M USD. Revenue FY2025 62.9M USD. Operating income FY2021 −93.32M USD. Operating income FY2022 −119.73M USD. Operating income FY2023 −99.82M USD. Operating income FY2024 −592.63M USD. Operating income FY2025 −213.06M USD. Net income FY2021 −86.85M USD. Net income FY2022 −104.2M USD. Net income FY2023 −75.8M USD. Net income FY2024 −567.94M USD. Net income FY2025 −204.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue62.9M USD7.87M USD———
Cost of goods sold8.44M USD7.08M USD———
Gross profit54.46M USD795K USD———
Research and development115.11M USD524.19M USD71.29M USD87.82M USD69.04M USD
Selling, general, and administrative151.56M USD69.23M USD28.53M USD31.92M USD24.28M USD
Operating expenses267.52M USD593.42M USD99.82M USD119.73M USD93.32M USD
Interest income21.43M USD27.06M USD24.61M USD7.45M USD2.96M USD
Interest expense13.68M USD341K USD———
Depreciation and amortization1.74M USD683K USD222K USD199K USD184K USD
Operating income−213.06M USD−592.63M USD−99.82M USD−119.73M USD−93.32M USD
Net income−204.63M USD−567.94M USD−75.8M USD−104.2M USD−86.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 4 misses, 3 met estimates
Average EPS surprise
+1.42%
11 comparable reports
Latest EPS result
-0.15
Estimate -0.14 · Miss by 5.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.05-0.04-0.12-0.21Q1 '25MissQ2 '25MetQ3 '25MetQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.15, estimate -0.14, surprise -7.14%, Miss. Q2 2025, reported May 7, 2025: actual -0.16, estimate -0.16, surprise 0.00%, Met estimate. Q3 2025, reported Aug 7, 2025: actual -0.17, estimate -0.17, surprise 0.00%, Met estimate. Q4 2025, reported Nov 3, 2025: actual -0.16, estimate -0.17, surprise +5.88%, Beat. Q1 2026, reported Mar 2, 2026: actual -0.11, estimate -0.11, surprise 0.00%, Met estimate. Q2 2026, reported May 4, 2026: actual 0.01, estimate -0.028, surprise +135.66%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.15, estimate -0.142, surprise -5.89%, Miss. Q4 2026, reported Nov 2, 2026: actual —, estimate -0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates89.86M60.01M30.15M303.57KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 5.71M USD, estimate 833.33K USD, surprise +585.32%, Beat. Q2 2025, reported May 7, 2025: actual 3.08M USD, estimate 357.14K USD, surprise +763.53%, Beat. Q3 2025, reported Aug 7, 2025: actual 4.83M USD, estimate 3.62M USD, surprise +33.39%, Beat. Q4 2025, reported Nov 3, 2025: actual 13.12M USD, estimate 36.82M USD, surprise -64.37%, Miss. Q1 2026, reported Mar 2, 2026: actual 41.87M USD, estimate 37.81M USD, surprise +10.71%, Beat. Q2 2026, reported May 4, 2026: actual 83.23M USD, estimate 66.22M USD, surprise +25.68%, Beat. Q3 2026, reported Aug 6, 2026: actual 31.69M USD, estimate 27.03M USD, surprise +17.24%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 35.77M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

10 ratings
Strong buy00%
Buy880%
Hold220%
Sell00%
Strong sell00%

ETFs holding NUVB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
56.13M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
44.18M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
17.78M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
15.89M
Weight
0.11%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
12.64M
Weight
0.12%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
11.9M
Weight
2.12%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
8.95M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
8.03M
Weight
0.03%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research NUVB

research.disclaimer